Cancer risk among 27 559 Swedish patients with ulcerative colitis, identified in two regional and population based cohorts and/or in the nationwide and population based register of inpatient care
| Cancer type | Ulcerative colitis (n = 27 559*) | |||||
|---|---|---|---|---|---|---|
| Regional cohorts (n = 4467) | Inpatient register (n = 26 036) | |||||
| O | E | SIR (95% CI) | O | E | SIR (95% CI) | |
| *The sum of 4467 and 26 036 exceeded 27 559 because of overlap between the cohorts. | ||||||
| CLL, chronic lymphocytic leukaemia. Cancers coded according to ICD-7. | ||||||
| Follow up from 1969 until 2001. Observed (O) and expected (E) number of cases, and standardised incidence ratio (SIR) with 95% confidence interval (95% CI). First year of follow up excluded. | ||||||
| All solid or haematopoietic sites (140–209) | 635 | 502.5 | 1.26 (1.2–1.4) | 2124 | 1739.9 | 1.22 (1.2–1.3) |
| All haematopoietic cancers (200–209) | 45 | 38.4 | 1.17 (0.9–1.6) | 147 | 132.6 | 1.11 (0.9–1.3) |
| Malignant lymphomas including CLL (200–202, 204.1) | 19 | 22.7 | 0.84 (0.5–1.3) | 78 | 79.6 | 0.98 (0.8–1.2) |
| Non-Hodgkin lymphomas (200, 202) | 17 | 15.5 | 1.10 (0.6–1.8) | 63 | 55.6 | 1.13 (0.9–1.4) |
| Hodgkin’s lymphoma (201) | 1 | 2.6 | 0.39 (0.01–2.2) | 8 | 7.7 | 1.03 (0.4–2.0) |
| CLL (204.1) | 1 | 4.6 | 0.22 (0.01–1.2) | 7 | 16.3 | 0.43 (0.2–0.9) |
| Multiple myeloma (203) | 6 | 6.7 | 0.90 (0.3–2.0) | 29 | 23.0 | 1.26 (0.8–1.8) |
| All leukaemias excluding CLL (204–207, 209) | 17 | 7.3 | 2.32 (1.4–3.7) | 35 | 24.8 | 1.13 (0.9–1.4) |
| Acute lymphatic leukaemia (204.0, 204.9) | 1 | 0.7 | 1.40 (0.04–7.8) | 2 | 2.4 | 0.84 (0.1–3.0) |
| Acute myeloid leukaemia (205.0, 205.9) | 9 | 3.6 | 2.53 (1.2–4.8) | 19 | 12.4 | 1.53 (0.9–2.4) |
| Chronic myeloid leukaemia (205.1) | 4 | 1.4 | 2.86 (0.8–7.3) | 10 | 4.3 | 2.35 (1.1–4.3) |
| Other leukaemias (206.0–1, 207.0–3, 207.9, 209) | 3 | 1.6 | 1.82 (0.4–5.3) | 4 | 5.7 | 0.70 (0.2–1.8) |
| Polycytaemia vera (209) | 3 | 1.6 | 1.86 (0.4–5.4) | 5 | 5.2 | 0.96 (0.3–2.2) |